Tag : investigational immunotherapy

Clinical Research, Pharma & Healthcare Financing

BeOne Medicines Reveals Breakthrough CLL & MCL Data at EHA 2025

Business Wire
by Business Wire0129
Clinical results from next-generation investigational therapies demonstrate potential for deep, durable responses that support the advancement of pivotal studies and future regulatory filings Phase 1...
Public Health, Disease Prevention & Wellness

Avidity Reports Positive Phase 1/2 FSHD Data for Del-Brax

PR Newswire
by PR Newswire0112
— Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid...
Workforce Development & Leadership

TriSalus Announces New CMS Code for TriNav® Mapping System

Business Wire
by Business Wire0156
TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery...